Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)

@inproceedings{Danaher2018PancancerAI,
  title={Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)},
  author={Patrick Danaher and Sarah Egan Warren and Rongze Lu and Josue Samayoa and Amy Sullivan and Irena Pekker and Brett Wallden and Francesco M. Marincola and Alessandra Cesano},
  booktitle={Journal for immunotherapy of cancer},
  year={2018}
}
The Tumor Inflammation Signature (TIS) is an investigational use only (IUO) 18-gene signature that measures a pre-existing but suppressed adaptive immune response within tumors. The TIS has been shown to enrich for patients who respond to the anti-PD1 agent pembrolizumab. To explore this immune phenotype within and across tumor types, we applied the TIS algorithm to over 9000 tumor gene expression profiles downloaded from The Cancer Genome Atlas (TCGA). As expected based on prior evidence… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 78 times over the past 90 days. VIEW TWEETS
1 Extracted Citations
105 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 105 references

Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors

  • FDA Approve
  • Available online: http://www. mrknewsroom.com…
  • 2018
1 Excerpt

Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT)

  • N Adra, SK Althouse, NR Ammakkanavar, M Radovich, C Albany, DJ Vaughn
  • J Clin Oncol. 2017;35:4520
  • 2018

Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143

  • DA Reardon, A Omuro, AA Brandes, J Rieger, A Wick, J Sepulveda
  • Neuro-Oncology. 2017;19(suppl_3):iii21. Danaher…
  • 2018

Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC)

  • ZA Wainberg, NH Segal, D Jaeger, KH Lee, J Marshall, SJ Antonia
  • J Clin Oncol. 2017;35:4071
  • 2018

3 Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma : CheckMate 143

  • DA Reardon, A Omuro, AA Brandes, J Rieger, A Wick, J Sepulveda
  • Neuro - Oncology
  • 2017

Similar Papers

Loading similar papers…